Drug Profile

Research programme: anticancer antibody therapeutics - Genagon Therapeutics

Alternative Names: Antibody based therapeutics - Genagon Therapeutics; Immuno-oncology therapies - Genagon Therapeutics

Latest Information Update: 28 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genagon Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2023 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
07 Feb 2019 Early research in Cancer in Sweden (Parenteral)
04 Feb 2019 Genagon Therapeutics enters into a worldwide license agreement with Ligand Pharmaceticals for the OmniAb platform (Genagon Therapeutics website, February 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com